Integra Lifesciences SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 21, 2026, 6:15 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedIntegra LifeSciences Q3 2026 revenue rises 2.3% to $411.2 million; GAAP EPS $0.19 and adjusted EPS $0.59 beat prior year, but Q4 guidance implies a decline
8-KOct. 19, 2026, 4:20 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Termination of a material definitive agreement · Creation of a direct financial obligation · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedIntegra LifeSciences Refinances Existing Debt with $450 Million 9.5% Senior Secured Notes and a $1.65 Billion Credit Facility
8-KOct. 9, 2026, 5:26 p.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
8-KOct. 2, 2026, 8:20 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
8-KSept. 8, 2026, 6:30 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
8-KJuly 29, 2026, 6:15 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits